Financial statements are reported in EUR and shown here converted to USD at today's exchange rate.
IFRX — InflaRx N.V.
$1.17
$-0.07 (-5.65%)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Market Cap
$172.42M
Forward P/E
-3.8x
52-Week Range
N/A
IFRX Price History
Revenue vs. Net Income
$32.3K
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
-$39.1M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
-107.9%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.0x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
394.5%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+14.2%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
